Clinical Trials
31 trialsNCT06607185 2026-05-26
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06704724 2026-05-22
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Terminated
NCT05462717 2026-05-15
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1 Active not recruiting
NCT05983133 2026-05-05
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Seagen Inc.
Phase 1 Terminated
NCT06447662 2026-04-20
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
Phase 1 Recruiting
NCT06625515 2026-02-24
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Phase 1 Terminated
NCT05544929 2026-01-06
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Active not recruiting
NCT04294160 2025-12-24
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Novartis
Phase 1 Terminated
NCT07179692 2025-10-02
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
Phase 1 Recruiting
NCT04853017 2025-09-05
AMPLIFY-201
Elicio Therapeutics
Phase 1 Completed
NCT02403505 2025-06-17
CEA+RC-BCG
Medicine Invention Design, Inc
Phase 1 Active not recruiting
NCT05943041 2025-02-14
Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer
GILongevity
Phase 1 Completed
NCT04046445 2025-01-29
KISIMA-01
Amal Therapeutics
Phase 1 Active not recruiting
NCT03251378 2024-09-25
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
Hutchmed
Phase 1 Completed
NCT06256055 2024-07-24
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
Phase 1 Unknown
NCT03454451 2023-12-21
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
Phase 1 Completed
NCT06126406 2023-11-13
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors
Chongqing Precision Biotech Co., Ltd
Phase 1 Recruiting
NCT05476341 2022-07-27
A Phase I Clinical Trial of Bevacizumab Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
Novartis
Phase 1 Completed
NCT00101972 2022-02-22
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
MacroGenics
Phase 1 Completed
NCT02933944 2022-01-26
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
Targovax ASA
Phase 1 Terminated
NCT03152370 2021-10-04
PRAER 1
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Completed
NCT00041691 2021-08-19
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery
Gilead Sciences
Phase 1 Terminated
NCT00959127 2020-09-16
A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer
Array BioPharma
Phase 1 Completed
NCT02574663 2019-10-02
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
TG Therapeutics, Inc.
Phase 1 Completed
NCT02205398 2019-01-22
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Novartis
Phase 1 Terminated
NCT01560377 2018-12-11
PILLAR II
Novadaq Technologies ULC, now a part of Stryker
Phase 1 Completed
NCT01380600 2016-01-08
Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
SillaJen, Inc.
Phase 1 Completed
NCT01286818 2014-10-06
A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)
Eli Lilly and Company
Phase 1 Completed
NCT00101894 2012-09-17
Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
Amgen
Phase 1 Completed
NCT00028405 2005-06-24
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
Light Sciences LLC
Phase 1 Completed